LEXINGTON, Ky. & MONTVALE, N.J.--(BUSINESS WIRE)--Intranasal Therapeutics, Inc. (ITI), a specialty pharmaceutical company focused on developing nasally delivered, preservative-free drug products, announced today the appointment of two key executives to its management team. Franz F. Hefti, Ph.D., who has a long history in developing neuroscience products at both emerging biotechnology and major pharmaceutical companies, has joined ITI as senior vice president and chief development officer. Richard A. Fisher, Ph.D., who additionally brings many years of experience in the development of both large and small molecule therapeutics including drugs for central nervous system indications, has joined ITI as senior vice president, Research & Development.
